2-乙基-5-氧代己酸 | 58045-80-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 2-乙基-5-氧代己酸
• 英文名称: α-ethyl-δ-oxocaproic acid
• 英文别名: 2-ethyl-5-oxo-hexanoic acid；2-Aethyl-5-oxo-hexansaeure；2-Ethyl-5-oxohexanoic acid
• CAS: 58045-80-0
• 化学式: C₈H₁₄O₃
• 分子量: 158.197
• InChiKey: ZLEMAINZCCYLAD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-乙基-5-氧代己酸 在 硫酸 、 aluminum isopropoxide 作用下， 以 异丙醇 为溶剂， 生成 2-Ethyl-5-hydroxy-hexanoic acid ethyl ester
  参考文献：
  名称：

  Saskisyan,O.A. et al., Journal of Organic Chemistry USSR (English Translation), 1969, vol. 5, p. 1601 - 1603

  摘要：

  DOI：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 sodium hydroxide 作用下， 生成 2-乙基-5-氧代己酸
  参考文献：
  名称：

  Kotschetkow; Gottich, Zhurnal Obshchei Khimii, 1958, vol. 28, p. 2732,2734; engl. Ausg. S. 2759

  摘要：

  DOI：

文献信息

• REACTION BEHAVIOR OF CARBON–CARBON AND CARBON–HYDROGEN BONDS IN SUPER ACIDS. CARBOXYLATION OF ALKYL METHYL KETONES WITH CARBON MONOXIDE AND WATER
  作者：Norihiko Yoneda、Haruhiko Sato、Tsuyoshi Fukuhara、Yukio Takahashi、Akira Suzuki

  DOI：10.1246/cl.1983.19

  日期：1983.1.5

  In a HF–SbF5 solution at −20∼30 °C under atmospheric pressure, ketones having alkyl groups with five or more carbon atoms underwent the reaction to give corresponding oxo carboxylic acids without any β-scission processes which occur readily in alkyl cations derived by protolysis of alkanes with seven or more carbon atoms. Tertiary C–H bond located at δ or further away from the oxo group in the substrates

  在 HF-SbF5 溶液中，在-20~30 °C 的大气压下，具有五个或更多碳原子的烷基的酮反应生成相应的氧代羧酸，而没有任何β-断裂过程，而β-断裂过程很容易发生在由以下方法衍生的烷基阳离子中具有七个或更多碳原子的烷烃的质子分解。位于 δ 处或远离底物中氧代基团的叔 C-H 键可以在 -20°C 下专门反应生成 (ω-1)-氧代-2,2-二甲基羧酸。
• DNA Methyltransferase inhibitors
  申请人：The Penn State Research Foundation

  公开号：EP1420021A1

  公开（公告）日：2004-05-19

  A compound of the formula or a pharmaceutically acceptable salt thereof, whereinR1, R2, and R3 are the same or different and are independently hydrogen, lower alkyl, aryl or substituted aryl, lower alkoxy, lower alkoxyalkyl, or cycloalkyl or cycloalkyl alkoxy, where each cycloalkyl group has from 3-7 members, where up to two of the cycloalkyl members are optionally hetero atoms selected from oxygen and nitrogen, and where any member of the alkyl, aryl or cycloalkyl group is optionally substituted with halogen, lower alkyl or lower alkoxy, aryl or substituted aryl, and whereR3 can be ribose, deoxyribose or phosphorylated derivatives thereof, whereinR1, R2, and R3 are not all hydrogen and whereinwhen R3 is ribose, deoxyribose or phosphorylated derivatives thereof, one of R1 or R2 is not hydrogen.

  该化合物的结构式为 或其药用可接受盐， 其中R1、R2和R3相同或不同，且独立地为氢、较低烷基、芳基或取代芳基、较低烷氧基、较低烷氧基烷基、环烷基或环烷基烷氧基，其中每个环烷基团具有3-7个成员，其中最多两个环烷基成员可选择为氧和氮，且烷基、芳基或环烷基团的任何成员可选择地取代有卤素、较低烷基或较低烷氧基、芳基或取代芳基，以及 其中R3可以是核糖、脱氧核糖或其磷酸化衍生物， 其中R1、R2和R3不全为氢， 当R3为核糖、脱氧核糖或其磷酸化衍生物时，R1或R2中的一个不是氢。
• Treatment of bacterial induced diseases using DNA methyl transferase inhibitors
  申请人：Benkovic J. Stephen

  公开号：US20050227933A1

  公开（公告）日：2005-10-13

  Methods for treating and/or preventing disease conditions caused or induced or aggravated by microbes, especially bacteria, by inhibiting DNA methyltransferase activity, such as by administering to an animal a DNA methyltransferase inhibitor, are disclosed, along with methods of reducing or ablating virulence in bacteria by inhibiting DNA methyltransferase activity.

  通过抑制DNA甲基转移酶活性，例如通过向动物施用DNA甲基转移酶抑制剂，来治疗和/或预防由微生物，特别是细菌引起、诱导或加重的疾病状况的方法被揭示，同时还揭示了通过抑制DNA甲基转移酶活性来减少或消除细菌的毒力的方法。
• METHODS OF NEUROPROTECTION USING NEUROPROTECTIVE STEROIDS AND A VITAMIN D
  申请人：Stein Donald G.

  公开号：US20110306579A1

  公开（公告）日：2011-12-15

  Described herein are compositions and methods for treating or preventing nervous system injury. In particular, the methods and compositions relate to the use of at least one neuroprotective steroid, such as progesterone, and vitamin D.

  本文描述了用于治疗或预防神经系统损伤的组合物和方法。具体而言，这些方法和组合物涉及使用至少一种神经保护类固醇，如孕激素，和维生素D。
• GLP-1 Derivatives, and Uses Thereof
  申请人：NOVO NORDISK A/S

  公开号：US20160200791A1

  公开（公告）日：2016-07-14

  The present invention relates to tri-acylated GLP-1 derivatives, acylated at positions corresponding to positions (18, 22, 30), (18, 26, 37), (18, 27, 37), (26, 30, 37), or (27, 30, 37) of the native human glucagon-like peptide 1 (GLP-1 (7-37) (SEQ ID NO: 1); or pharmaceutically acceptable salts, amides, or esters thereof. The acylated side chains comprise a protracting moiety selected from Chem. 1: HOOC—(CH 2 ) 16 —CO—*, Chem. 1a: HOOC—(CH 2 ) 18 —CO—*, and Chem. 2: HO 3 S—(CH 2 ) 15 —CO—*, and the protracting moieties are connected, via a linker, to a Lys residue of the GLP-1 peptide. The GLP-1 peptide has a maximum of seven amino acid changes as compared to GLP-1 (7-37) (SEQ ID NO: 1). The invention also relates to intermediate products in the form of novel GLP-1 analogues, as well as to pharmaceutical compositions and uses of the derivatives and analogues, in particular for the treatment of type 2 diabetes. The derivatives have very long half-lives while maintaining a satisfactory potency, which makes them potentially suitable for once-monthly administration.

  本发明涉及三酰化GLP-1衍生物，酰化位置与人源胰高血糖素样肽1（GLP-1（7-37）（序列号：1））的位置（18、22、30）、（18、26、37）、（18、27、37）、（26、30、37）或（27、30、37）相对应，并且其药学上可接受的盐、酰胺或酯。酰化侧链包括从化学1: HOOC—(CH2)16—CO—*、化学1a: HOOC—(CH2)18—CO—*和化学2: HO3S—(CH2)15—CO—*中选择的延长基团，并且通过连接器连接到GLP-1肽的一个赖氨酸残基。与GLP-1（7-37）（序列号：1）相比，GLP-1肽最多有七个氨基酸变化。该发明还涉及作为新GLP-1类似物的中间产物，以及衍生物和类似物的药物组合物和用途，特别是用于治疗2型糖尿病。这些衍生物具有非常长的半衰期，同时保持了令人满意的效力，这使它们有可能适合每月一次的给药。